12:53 PM
 | 
Sep 01, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CoCrystal reports Phase I data for HCV candidate CC-31244

CoCrystal Pharma Inc. (OTCQB:COCP) reported data from a Phase Ia/Ib trial in 42 healthy volunteers and 15 patients with HCV genotype 1 infection showing that CC-31244 led to no dose-limiting toxicities (DLTs), discontinuations due to adverse events or serious adverse events.

CC-31244, dosed at 400 or 600 mg...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >